Table I.

Conditioning regimens and graft-versus-host disease prophylaxis.

Regimen*	N (%)
Myeloablative conditioning regimens	38 (26)
Fludarabine-Melphalan	7 (5)
Melphalan	6 (4)
Melphalan-TBI	10 (7)
Busufan-Cyclosporin-Thiotepa	6 (4)
Others	9 (6)
Reduced-intensity conditioning regimens	110 (74)
Fludarabine-Melphalan	99 (67)
TBI	6 (4)
Others	5 (3)
Graft-versus-host disease prophylaxis	147(100)
Cyclophosphamide	4 (3)
Cyclophosphamide-MTX	12 (8)
Cyclophosphamide-MMF	6 (4)
None**	6 (4)
Tacrolimus	6 (4)
Tacrolimus-MTX	104 (70)
Others	11 (7)
Missing	2 (1)

TBI, total-body irradiation; MTX, methotrexate; MMF, mycophenolate mofetil;

^*One patient could not be assigned to myeloablative or reduced intensity conditioning due to missing data.

^**These patients received transplantation from human leukocyte antigen–identical twin siblings.